[go: up one dir, main page]

WO2013016598A3 - Procédés pour réduire une lésion de reperfusion en utilisant un porteur de monoxyde de carbone à base d'hémoglobine - Google Patents

Procédés pour réduire une lésion de reperfusion en utilisant un porteur de monoxyde de carbone à base d'hémoglobine Download PDF

Info

Publication number
WO2013016598A3
WO2013016598A3 PCT/US2012/048450 US2012048450W WO2013016598A3 WO 2013016598 A3 WO2013016598 A3 WO 2013016598A3 US 2012048450 W US2012048450 W US 2012048450W WO 2013016598 A3 WO2013016598 A3 WO 2013016598A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbon monoxide
hemoglobin
methods
based carbon
reperfusion injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/048450
Other languages
English (en)
Other versions
WO2013016598A2 (fr
Inventor
Mark Young
Kim D. Vandegriff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangart Inc
Original Assignee
Sangart Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangart Inc filed Critical Sangart Inc
Publication of WO2013016598A2 publication Critical patent/WO2013016598A2/fr
Publication of WO2013016598A3 publication Critical patent/WO2013016598A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne généralement des procédés pour réduire une lésion de reperfusion. Spécifiquement, la présente invention concerne l'administration d'un porteur de monoxyde de carbone à base d'hémoglobine à un sujet, avant ou après chirurgie, pour réduire une lésion résultant d'une reperfusion par administration de monoxyde de carbone et d'oxygène à un tissu ischémique.
PCT/US2012/048450 2011-07-27 2012-07-27 Procédés pour réduire une lésion de reperfusion en utilisant un porteur de monoxyde de carbone à base d'hémoglobine Ceased WO2013016598A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512335P 2011-07-27 2011-07-27
US61/512,335 2011-07-27

Publications (2)

Publication Number Publication Date
WO2013016598A2 WO2013016598A2 (fr) 2013-01-31
WO2013016598A3 true WO2013016598A3 (fr) 2013-03-21

Family

ID=47601767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048450 Ceased WO2013016598A2 (fr) 2011-07-27 2012-07-27 Procédés pour réduire une lésion de reperfusion en utilisant un porteur de monoxyde de carbone à base d'hémoglobine

Country Status (1)

Country Link
WO (1) WO2013016598A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018138360A1 (fr) 2017-01-28 2018-08-02 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Substituts sanguins transportant de l'oxygène et leur utilisation en tant que véhicules d'administration
WO2019018403A1 (fr) 2017-07-18 2019-01-24 Virtech Bio, Llc Substituts sanguins comprenant de l'hémoglobine et procédés de fabrication
CN114377155B (zh) * 2022-01-14 2023-11-10 吴诗熳 一种造影剂、造影剂的制备方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888249A (en) * 1973-11-02 1975-06-10 David L Spencer Arterial infusion catheter
US20060234915A1 (en) * 2005-03-07 2006-10-19 Sangart, Inc. Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissue using heme proteins as carriers
US7625862B2 (en) * 2002-01-11 2009-12-01 Sangart, Inc. Method for making a high oxygen affinity modified hemoglobin for oxygen transport
US20120196270A1 (en) * 2011-02-02 2012-08-02 Sangart, Inc. Methods for preserving an organ for transplantation using a hemoglobin-carbon monoxide complex

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888249A (en) * 1973-11-02 1975-06-10 David L Spencer Arterial infusion catheter
US7625862B2 (en) * 2002-01-11 2009-12-01 Sangart, Inc. Method for making a high oxygen affinity modified hemoglobin for oxygen transport
US20060234915A1 (en) * 2005-03-07 2006-10-19 Sangart, Inc. Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissue using heme proteins as carriers
US20090082257A1 (en) * 2005-03-07 2009-03-26 Sangart, Inc. MalPEG-Hb conjugate- containing compositions for delivering carbon monoxide (CO) to cells
US20120196270A1 (en) * 2011-02-02 2012-08-02 Sangart, Inc. Methods for preserving an organ for transplantation using a hemoglobin-carbon monoxide complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BURMEISTER M ET AL.: "Effect of prophylactic or therapeutic application of bovine haemoglobin HBOC-200 on ischaemia-reperfusion injury following acute coronary ligature in rats.", BR J ANAESTH, vol. 95, 2005, pages 737 - 745 *
CRETEUR ET AL.: "Potential Uses of Hemoglobin-based Oxygen Carriers in Critical Care Medicine", vol. 25, 2009, pages 311 - 324 *

Also Published As

Publication number Publication date
WO2013016598A2 (fr) 2013-01-31

Similar Documents

Publication Publication Date Title
MX2014001180A (es) Moduladores del transporte nuclear y usos de los mismos.
EP4234545A3 (fr) Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations
EA026892B9 (ru) ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1
TW201144301A (en) Processes for preparing linezolid
PT2759341T (pt) Catalisador de paládio/carbono contendo enxofre, método de preparação do mesmo e método de preparação de antioxidante de p-fenilenodiamina
MX359651B (es) Antagonistas de cxcr7.
IN2014DN09782A (fr)
WO2012065102A8 (fr) Analogues dipeptidiques de cystéine protégée par s-t-butyle et composés associés
MY189659A (en) Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
MX360030B (es) Metodos para tratar el trastorno bipolar.
WO2012065110A3 (fr) Analogues de cystéine s-protégés et composés associés
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
WO2013020024A3 (fr) Composés de maléimide et méthodes de traitement
MX2013013685A (es) Metodo para tratar articulos con dioxido de carbono.
WO2012131001A3 (fr) Coussin pour interface patient
WO2011069159A3 (fr) Composés de bis[thio-hydrazide amide] pour le traitement de la leucémie
EP2558150A4 (fr) Canule nasale pour échantillonnage de dioxyde de carbone
WO2013016598A3 (fr) Procédés pour réduire une lésion de reperfusion en utilisant un porteur de monoxyde de carbone à base d'hémoglobine
MX358785B (es) Hemoglobina pegilada reticulada con diaspirina.
GEP20125680B (en) Carbonic and sulphuric acid salts of 3-(2,2,2-trimethylhydra-zinium) ropionate esters and their use for 3-(2,2,2-rimethyl- hydrazinium) propionate dihydrate preparation
WO2011000945A3 (fr) Aminoalcamides pour une utilisation dans le traitement de maladies inflammatoires, dégénératives ou démyélinisantes du système nerveux central
WO2012116151A3 (fr) Composés soufrés aromatiques substitués et procédés de leur utilisation
WO2012123519A3 (fr) Analogues de l'insuline humaine et dérivés comprenant des substitutions de cystéine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12817689

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12817689

Country of ref document: EP

Kind code of ref document: A2